ArticleAAPS PharmSciTech2026
Identifying Optimal Drug Loading in Stable Amorphous Solid Dispersion Formulations: A Rheological Approach.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synthetic polymers play a crucial role in enhancing the performance of drug formulations by enabling controlled release, improving bioavailability, and ensuring stability. Copovidone is frequently employed as an excipient in hot-melt extrusion (HME) to augment the solubility of active pharmaceutical ingredients (APIs). However, this method faces two significant challenges: identifying the optimal copovidone/API composition (the solubility of the crystalline API in the copovidone matrix) and the inadequate time-dependent stability of some amorphous APIs in the copovidone matrix. To overcome these issues, it's crucial to accurately assess the solubility and miscibility of the crystalline drug within the polymer, which is essential for developing a stable polymer/API amorphous system. This study utilized Plasdone
Indexed as
Identifiers
42120800What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.